Literature DB >> 6877322

The declining specificity of exercise radionuclide ventriculography.

A Rozanski, G A Diamond, D Berman, J S Forrester, D Morris, H J Swan.   

Abstract

Although exercise radionuclide ventriculography was initially reported to be a highly specific test for coronary-artery disease, later studies reported a high false-positive rate. To verify this turnabout, we analyzed the responses in 77 angiographically normal patients; 32 were studied from 1978 to 1979 (the early period), and 45 from 1980 to 1982 (the recent period). Most patients studied in the early period had normal responses (94 per cent for ejection fraction and 84 per cent for wall motion). In contrast, normal responses were less frequent in patients studied in the recent period (49 per cent for ejection fraction and 36 per cent for wall motion, P less than 0.001). The probability of coronary disease before testing was higher in these patients (38 vs. 7 per cent, P less than 0.001). More patients studied in the recent period underwent radionuclide ventriculography before angiography (78 vs. 22 per cent, P less than 0.001), and more of these prior studies had abnormal results than those performed after angiography (55 vs. 6 per cent, P less than 0.0001). Thus, two factors are responsible for the temporal decline in specificity: a change in the population being tested (pretest referral bias) and a preferential selection of patients with a positive test response for coronary angiography (post-test referral bias).

Entities:  

Mesh:

Year:  1983        PMID: 6877322     DOI: 10.1056/NEJM198309013090902

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  53 in total

Review 1.  Designing studies to ensure that estimates of test accuracy are transferable.

Authors:  Les Irwig; Patrick Bossuyt; Paul Glasziou; Constantine Gatsonis; Jeroen Lijmer
Journal:  BMJ       Date:  2002-03-16

Review 2.  Misguided efforts and future challenges for research on "diagnostic tests".

Authors:  A R Feinstein
Journal:  J Epidemiol Community Health       Date:  2002-05       Impact factor: 3.710

3.  Diagnostic accuracy of dipyridamole technetium 99m-labeled sestamibi myocardial tomography for detection of coronary artery disease.

Authors:  D D Miller; L T Younis; B R Chaitman; H Stratmann
Journal:  J Nucl Cardiol       Date:  1997 Jan-Feb       Impact factor: 5.952

4.  Treadmill test scores: attributes and limitations.

Authors:  L J Shaw; R Hachamovitch; A E Iskandrian
Journal:  J Nucl Cardiol       Date:  1997 Jan-Feb       Impact factor: 5.952

5.  Emergency department assessment of patients with acute chest pain: myocardial perfusion imaging, blood tests, or both?

Authors:  Kevin C Allman; S Ben Freedman
Journal:  J Nucl Cardiol       Date:  2004 Jan-Feb       Impact factor: 5.952

6.  Referral bias: a difficult but important topic.

Authors:  Raymond J Gibbons
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

7.  Comparison of diagnostic performances of three different software packages in detecting coronary artery disease.

Authors:  Raffaele Giubbini; Francesco Bertagna
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11       Impact factor: 9.236

8.  Equilibrium gated radionuclide angiocardiography: Its invention, rise, and decline and … comeback?

Authors:  Frans J Th Wackers
Journal:  J Nucl Cardiol       Date:  2016-01-27       Impact factor: 5.952

Review 9.  Anaesthesia for abdominal aortic surgery--a review (Part I).

Authors:  A J Cunningham
Journal:  Can J Anaesth       Date:  1989-07       Impact factor: 5.063

10.  Diagnostic accuracy of gated Tc-99m sestamibi stress myocardial perfusion SPECT with combined supine and prone acquisitions to detect coronary artery disease in obese and nonobese patients.

Authors:  Daniel S Berman; Xingping Kang; Hidetaka Nishina; Piotr J Slomka; Leslee J Shaw; Sean W Hayes; Ishac Cohen; John D Friedman; James Gerlach; Guido Germano
Journal:  J Nucl Cardiol       Date:  2006 Mar-Apr       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.